Windlas Biotech: revenue +18.7% YoY, margin squeeze caps PAT growth at 1.4%
PAT +1.42% YoY · revenue +18.67% · margins compressing
₹263.91 Cr
+18.67% YoY
₹18.05 Cr
+1.42% YoY
6.74%
-1.1pp YoY
₹8.75
Windlas Biotech's standalone revenue grew 18.7% YoY to ₹263.9 Cr in Q2 FY27 (quarter ended 30-Sep-2026), extending its growth run from ₹222.4 Cr a year ago, and rose 6.4% sequentially from ₹248.1 Cr in Q1 FY27. Profit after tax grew just 1.4% YoY to ₹18.05 Cr (₹17.80 Cr a year ago) and 2.3% QoQ (₹17.65 Cr) — profit growth trailing revenue growth by a wide margin, which is the core story of the quarter. Neither period carries exceptional items, so the gap is a genuine margin effect rather than a base-effect distortion. No Q2 FY27-specific street estimates for Windlas turned up in a search, so the print cannot be graded against consensus this quarter (vsStreet: unknown).
Q2 FY-2027 vs prior quarters
Operating margin (EBITDA/revenue) came in near 11.1%, down from 12.8% a year ago though up slightly from 10.75% in Q1 FY27; net margin was 6.8%, down from 7.9% YoY and roughly flat sequentially (7.0%) — margin compression is a YoY phenomenon, not a QoQ one. Basic EPS of ₹8.75 rose 3.2% YoY and 3.4% QoQ, outpacing PAT growth, because the share count fell roughly 2.2% after the company completed a ₹47 Cr tender-offer buyback of 470,000 shares this half, on top of a ₹130 Cr FY26 dividend payout; both calls on cash were funded partly by a ₹16.4 Cr rise in short-term borrowings (₹29.9 Cr to ₹46.2 Cr).
The stock went into the print at ₹922, down 11% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
Plant 6 commercialization end of H1 FY27. Capacity potential: ₹1,100 Cr via Plant 6, expandable ₹100–150 Cr via debottlenecking. No FY27 full-year revenue target disclosed; management focuses on disciplined execution over aggressive growth targets.
— This quarter: met
Management had guided on the Q1 FY27 call that Plant 6 would commercialize by the end of H1 FY27 — i.e., by this quarter-end — adding capacity toward ₹1,100 Cr of revenue. This filing does not name Plant 6 directly, but the balance sheet is consistent with that timeline: capital work-in-progress fell to nil from ₹56.2 Cr as of March 2026, while property, plant & equipment rose ₹29 Cr and right-of-use assets rose ₹35 Cr — a capitalization pattern that lines up with a facility going live in the exact window management flagged. No management press release accompanied this filing, so there is no fresh management commentary to check the numbers against this quarter. Separately, the same board meeting approved a leadership transition — Ashok Kumar Windlass stepped down as Whole-time Director as part of long-term succession planning, continuing as Senior Management Personnel/Founder President, while Hitesh Windlass was appointed Chairman — and the company had disclosed a cybersecurity incident on 30-Oct-2026, five days before results, with no financial impact quantified anywhere in this statement.
W1
OPM trajectory: slipped YoY to ~11.1% from 12.8% — watch whether Plant 6's capitalization (this half) lifts operating leverage from Q3 FY27, per management's ₹1,100 Cr capacity guidance
W2
Working capital: trade receivables up ₹60.9 Cr and trade payables up ₹67.3 Cr in H1 FY27, partly funded by a ₹16.4 Cr rise in short-term borrowings — watch if growth keeps absorbing cash
W3
EPS quality: share count down ~2.2% post-buyback is currently doing more work than PAT growth (+1.4% YoY) — confirm EPS growth isn't solely buyback-driven once PAT growth normalizes
Standalone only — company stopped preparing consolidated statements from 1-Apr-2026 after dissolving its sole, non-operating US subsidiary (Windlas Inc.); source figures in ₹ Million, converted to ₹ Cr (÷10); no exceptional items either period so no YoY adjustment needed; our year-ago comparator was tagged 'consolidated' but the dissolved subsidiary was non-operating, so divergence from standalone is expected to be negligible.
Informational and educational content only. Not investment advice.